Wilmington Savings Fund Society FSB Sells 14,428 Shares of Johnson & Johnson (NYSE:JNJ)

Wilmington Savings Fund Society FSB cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 486,710 shares of the company's stock after selling 14,428 shares during the period. Johnson & Johnson comprises about 1.3% of Wilmington Savings Fund Society FSB's investment portfolio, making the stock its 11th biggest holding. Wilmington Savings Fund Society FSB's holdings in Johnson & Johnson were worth $70,388,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new position in Johnson & Johnson in the third quarter worth about $31,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson in the third quarter worth about $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its holdings in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after acquiring an additional 91 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $1.05 on Friday, hitting $156.20. 6,402,249 shares of the company were exchanged, compared to its average volume of 9,304,454. The company's 50 day moving average price is $147.87 and its two-hundred day moving average price is $156.00. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $376.08 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the firm posted $2.29 EPS. The business's revenue was up 5.3% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson's payout ratio is currently 74.59%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on JNJ shares. Bank of America cut their price target on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target on the stock. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Finally, Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $170.67.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.